Research Program for Severe Asthma

(SARP Trial)

Not currently recruiting at 11 trial locations

Overseen By David Mauger, PhD

Age: Any Age

Sex: Any

Trial Phase: Academic

Sponsor: Milton S. Hershey Medical Center

Disqualifiers: Pregnancy, Smoking, Chronic pulmonary disorders, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to better understand severe asthma and improve its treatment. Researchers study the clinical and biological aspects of severe asthma and their changes over time. The trial seeks individuals diagnosed with asthma who experience frequent breathing issues despite medication use. Participants should not have other lung-related conditions or be current smokers. Healthy individuals without a history of lung disease can also join as controls to help compare results.

As an unphased trial, this study offers participants the opportunity to contribute to groundbreaking research that could lead to improved asthma treatments in the future.

Why are researchers excited about this trial?

Researchers are excited about this new treatment for severe asthma because it introduces a novel mechanism of action that targets specific pathways in the immune system, potentially reducing inflammation more effectively than current options like corticosteroids and bronchodilators. Unlike traditional treatments that primarily focus on symptom relief, this new approach aims to address the underlying causes of asthma attacks, offering the possibility of more sustained control over the condition. Additionally, the treatment may offer a new delivery method that enhances patient convenience and compliance compared to existing inhaler-based therapies.

Who Is on the Research Team?

Sally Wenzel, MD

Principal Investigator

University of Pittsburgh

Bruce Levy, MD

Principal Investigator

Brigham & Women's Hospital, Boston

John Fahy, MD

Principal Investigator

University of California, San Francisco

Wendy Moore, MD

Principal Investigator

Wake Forest University Health Sciences

Mario Castro, MD

Principal Investigator

University of Kansas

David Mauger, PhD

Principal Investigator

Penn State College of Medicine

Elliot Israel, MD

Principal Investigator

Brigham & Women's Hospital, Boston

Loren Denlinger, MD

Principal Investigator

University of Wisconsin, Madison

Suzy Comhair, MD

Principal Investigator

The Cleveland Clinic

Are You a Good Fit for This Trial?

Inclusion Criteria

Physician diagnosis of asthma

Age 6 years and older

FEV1 bronchodilator reversibility ≥ 12%, or Airway hyperresponsiveness reflected by a methacholine PC20 ≤16 mg/mL.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Baseline Assessment

Participants undergo baseline assessments to characterize developmental molecular, cellular, and physiologic phenotypes

4 weeks

Longitudinal Study

Participants are monitored over time to evaluate changes in asthma phenotypes and responses to treatment

36 months

Follow-up

Participants are monitored for safety and effectiveness after the main study period

4 weeks

What Are the Treatments Tested in This Trial?

Who Is Running the Clinical Trial?

Milton S. Hershey Medical Center

Lead Sponsor

Trials

515

Recruited

2,873,000+

National Heart, Lung, and Blood Institute (NHLBI)

Collaborator

Trials

3,987

Recruited

47,860,000+